Table 1. Trials’ Characteristics (selected arms for the analysis).
| Author | Phase | Disease Type | Drug | Treatment Line | PD-L1Cut-Off (%) | PD-L1 Subgroup | Sample size | ORR(%) |
|---|---|---|---|---|---|---|---|---|
| Weber et al, JCO 2013 [39] | I | Melanoma | Nivolumab | ≥2° | 5 | Positive | 12 | 67.0 |
| Negative | 32 | 19.0 | ||||||
| Hamid et al, ASCO 2013 [33] | I | Melanoma | MPDL3280A | Mixed | 5 | Positive | 15 | 27.0 |
| Negative | 15 | 20.0 | ||||||
| Hodi et al, ASCO 2014 [35] | I | Melanoma | Nivolumab | ≥2° | 5 | Positive | 18 | 44.0 |
| Negative | 23 | 13.0 | ||||||
| Sznol et al, ASCO 2014 [38] | I | Melanoma | Nivolumab | ≥2° | 5 | Positive | 22 | 35.0 |
| Negative | 57 | 59.0 | ||||||
| Robert et al, NEJM 2015 [24] | III | Melanoma | Nivolumab | 1° | 5 | Positive | 74 | 52.7 |
| Negative | 136 | 33.1 | ||||||
| Weber et al, LO 2015 [10] | III | Melanoma | Nivolumab | ≥2° | 5 | Positive | 55 | 43.6 |
| Negative | 64 | 20.3 | ||||||
| Kefford et al, ASCO 2014 [36] | I | Melanoma | Pembrolizumab | Mixed | 1 | Positive | 83 | 49.0 |
| Negative | 30 | 13.0 | ||||||
| Rizvi et al, CMSTO 2014 [43] | I | NSCLC | Nivolumab | 1° | 5 | Positive | 26 | 31.0 |
| Negative | 21 | 10.0 | ||||||
| Antonia et al, CMSTO 2014 [44] | I | NSCLC | Nivolumab | 1° | 5 | Positive | 16 | 19.0 |
| Negative | 22 | 14.0 | ||||||
| Herbst et al, Nature 2014 [34] | I | NSCLC | MPDL3280A | ≥2° | 5 | Positive | 9 | 27.0 |
| Negative | 37 | 24.0 | ||||||
| Gettinger et al, JCO 2015 [45] | I | NSCLC | Nivolumab | ≥2° | 5 | Positive | 33 | 15.0 |
| Negative | 35 | 14.0 | ||||||
| Rizvi et al, LO 2015 [11] | II | NSCLC | Nivolumab | ≥2° | 5 | Positive | 25 | 24.0 |
| Negative | 51 | 14.0 | ||||||
| Garon et al, NEJM 2015 [46] | I | NSCLC | Pembrolizumab | ≥2° | 1 | Positive | 159 | 23.0 |
| Negative | 35 | 9.0 | ||||||
| Rizvi et al, ASCO 2014 [37] | I | NSCLC | Pembrolizumab | 1° | 1 | Positive | 42 | 26.0 |
| Cho et al, ASCO 2013 [42] | I | GU | MPDL3280A | Mixed | 5 | Positive | 10 | 20.0 |
| Negative | 21 | 10.0 | ||||||
| Powles et al, Nature 2014 [15] | I | GU | MPDL3280A | ≥2° | 5 | Positive | 7 | 29.0 |
| Negative | 58 | 26.0 | ||||||
| Motzer et al, JCO 2014 [14] | II | GU | Nivolumab | ≥2° | 5 | Positive | 29 | 31.0 |
| Negative | 78 | 18.0 | ||||||
| Choueiri et al, ESMO 2014 [32] | I | GU | Nivolumab | Mixed | 5 | Positive | 18 | 22.0 |
| Negative | 38 | 8.0 | ||||||
| Hammers et al, ESMO 2014 [40] | I | GU | Nivolumab | Mixed | 1 | Positive | 16 | 50.0 |
| Negative | 20 | 55.0 | ||||||
| Plimack et al, ESMO 2014 [41] | I | GU | Pembrolizumab | Mixed | 1 | Positive | 33 | 24.1 |
PD-L1: programmed death-ligand-1; ORR: overall response rate; NSCLC: non-small cell lung cancer.